The efficacy and safety of first‐line anti‐PD‐1/PD‐L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‐analysis of phase III randomized controlled trials

ABSTRACT: Immunotherapy-based regiments have potential as first-line treatment for advanced gastric esophageal cancer. The present study aimed to conduct a meta-analysis of the association between the efficacy and safety of first-line immunotherapy combined with chemotherapy in patients with unresectable locally advanced or metastatic gastric esophageal cancer. Subgroup analysis of patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) was conducted to identify the characteristics of patients with immune benefit and to provide a decision-making basis for clinical practice. PubMed, Embase, Cochrane Library and other databases were searched to collect randomized controlled trials of immunotreatment-based regimens (experimental group) versus conventional first-line chemotherapy r

SUBMITTER: Duan X 

PROVIDER: S-EPMC10133786 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature